Ceftobiprole
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Total Hip Replacement Surgery
Conditions
Total Hip Replacement Surgery
Trial Timeline
Apr 1, 2009 → Feb 1, 2010
NCT ID
NCT00771524About Ceftobiprole
Ceftobiprole is a phase 1 stage product being developed by Basilea Pharmaceutica for Total Hip Replacement Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT00771524. Target conditions include Total Hip Replacement Surgery.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00965042 | Phase 1 | Completed |
| NCT00771524 | Phase 1 | Completed |
| NCT00771719 | Phase 1 | Terminated |
| NCT01026740 | Phase 1 | Completed |
Competing Products
11 competing products in Total Hip Replacement Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirin | Daiichi Sankyo | Approved | 85 |
| LY517717 + enoxaparin | Eli Lilly | Phase 2 | 52 |
| Glucagon receptor antagonist LY2409021 + Placebo | Eli Lilly | Pre-clinical | 23 |
| Clopidogrel + Ticagrelor | AstraZeneca | Approved | 85 |
| Zoledronic acid 5mg | Novartis | Approved | 85 |
| LNA043 + Placebo | Novartis | Phase 1 | 33 |
| Denosumab | Amgen | Phase 2 | 51 |
| 48-hour ropivacaine infusions + Single dose ropivacaine + Patient controlled analgesics | Sanofi | Pre-clinical | 22 |
| Exacyl® | Bayer | Phase 3 | 74 |
| Enoxaparin + Apixaban + BAY1213790 | Bayer | Phase 2 | 49 |
| etoricoxib (MK0663) 120 mg + Comparator: Placebo + etoricoxib (MK0663) 90 mg | Organon | Phase 3 | 72 |